Congratulations to Fractyl Health who presented compelling preclinical Rejuva data at #ADA 2024 last weekend, which was selected as the #1 abstract out of 8,000 submissions.
Gilmartin Group LLC’s Post
More Relevant Posts
-
Physician and Scientist | Passionate Educator and Researcher | Genetics & Personalized Medicine | Enthusiastic transformer in Medical AI Applications
🌍 Over 7,000 rare and undiagnosed diseases exist, yet only 5-7% have treatments—leaving the majority without options. Only about 500 have treatments approved by the U.S. FDA. Even for those with approved treatments, discovering new drugs can offer alternative options that cause fewer side effects and replace drugs that are ineffective for certain patient groups. However, identifying new therapeutic opportunities for diseases with limited treatment options remains a challenge, as existing algorithms often perform poorly. 💡 That’s where (zero-shot drug repurposing) comes in! By identifying new uses for approved drugs gives the potential to discover therapies for diseases with no current treatments. The solution: TxGNN, a groundbreaking graph-based foundation model designed to solve this challenge! 🔬 TxGNN uses self-supervised learning on a massive biomedical knowledge graph to predict both drug *indications* and *contraindications* for over 17,000 diseases, many of which have zero FDA-approved treatments. 🚀 What sets TxGNN apart? Its unique disease pooling module that groups diseases based on mechanistic similarities, allowing it to perform even with limited data. Ready to explore? 👉 Check out TxGNN’s interactive visualization tool at TxGNN.org to see how it's paving the way for drug repurposing and giving hope to the untreated! and the published paper: https://lnkd.in/dXTMbY5b #HealthcareInnovation #DrugRepurposing #RareDiseases #TxGNN #AI
To view or add a comment, sign in
-
Metrodora Foundation is thrilled to announce the launch of MetX - a landmark study to deepen the biological understanding of chronic, complex conditions. The role of the Metrodora Foundation is to accelerate cures. We enlisted biopharma experts to explain why there weren’t more companies developing treatments for our patients, despite how large the need is. Their resounding response was that there isn’t enough quality patient data available to create a robust enough understanding of these diseases at the biological level. Therefore, it remains too risky for most pharma companies to prioritize these conditions. The most important information that biopharma asked us to compile is a 360 degree view of our patients - clinical information, like test results and electronic health information from patient visits, patient-reported information via surveys and wearables data, and in-depth biological information from genomics to immune profiling. No one else has collected such a comprehensive, longitudinal view of these patients. That is exactly what we’re launching today. And we’re doing so using patient-friendly technology that makes it easy for patients to share data, participate in research, and get value back in return. Read our announcement to learn more about how we're working with our partners to revolutionize collaborative research and improve patient outcomes. #LONGCOVID #MECFS #POTS #MIGRAINE #SJOGRENS #EDS #MCAS #CHRONICPAIN #FIBROMYALGIA #ENDOMETRIOSIS #FOODALLERGY #IBS #IBD #CHRONICILLNESS #INVISIBLEILLNESS https://lnkd.in/eZC2QGPq
Announcing Met X: The Next Step in Understanding Chronic, Complex Conditions
metrodora.org
To view or add a comment, sign in
-
Our researchers utilize vast multi-omics datasets from both public and private sources to advance disease research, diagnostics, and treatment development. These resources are invaluable in exploring the drug discovery landscape. 📊🌐 Learn more about what we’re doing! 👇 https://lnkd.in/dEDuFUmP #Bioinformatics #OmicsData #DrugDevelopment #Delta4 #TechBio
To view or add a comment, sign in
-
Hats off to Insilico Medicine, Alex Zhavoronkov, Feng Ren, 4B Technologies, Ltd for completing phase 2 patient enrollment for the fully AI-developed ALS drug. By target identification with PandaOmics, and further drug development, this partnership gave hope to tackling the currently untreatable disease in less than 2 years since the project started. This highlights the power of #AI drug development, and it's crucial role in minimizing the burden of disease. Kudos!
To view or add a comment, sign in
-
If you're at the #ALS Drug Development Summit this week, don't miss QurAlis' presentation covering how our Digital Twin Generators can support their ANQUR study and future studies for QRL-201. #clinicaltrials #ALSdrugdevelopmentsummit2024 #AI #machinelearning
QurAlis presents! QurAlis' head of development Emma Bowden, PhD, will present an overview of our Phase 1 ANQUR clinical trial evaluating QRL-201 at the 3rd ALS Drug Development Summit. QRL-201 is a first-in-class #STATHMIN-2 (#STMN2) #precisionmedicine for #ALS. ANQUR is the first-ever study to evaluate a therapy that rescues STMN2 expression in ALS patients and could halt disease progression. STMN2 is a well-validated protein important for neural repair and axonal stability, the expression of which is significantly decreased in nearly all ALS patients. QurAlis is exploring the use of the Unlearn.AI Digital Twin Generators in ANQUR with the goal of supporting both ANQUR and future studies for QRL-201. #neurodegenerativediseases https://bit.ly/3WLZB8l
Expert Speakers - 3rd ALS Drug Development Summit
als-drug-development.com
To view or add a comment, sign in
-
Exciting News: myriamed GmbH ´s Arne Östlind is attending the health.tech conference in munich from 05-06.2024 ! myriamed GmbH´s ultimate aim is to contribute to the development of new cures for today‘s most debilitating diseases by defining wanted and unwanted drug effects at the earliest possible time point. With 20+ years of experience in cell and engineered muscle models we are determined to provide our customers with standardized and individualized solutions to move preclinical drug development closer to clinical reality. myriamed GmbH´s wholly human platforms allow for detailed mode of action analyses and a rationale dosing strategy for early clinical trials. This is particularly useful in cases where animal models largely fail, i.e., in the development of new therapies targeting specific human molecules (protein, RNA, DNA). Want to meat Arne Östlind in person and talk about the myriamed GmbH approach? Just use the health tech app: https://lnkd.in/dz-wqwHr or contact us via the myriamed GmbH website. More about myriamed GmbH: www.myriamed.com More about the health.tech conference: https://www.health.tech/
To view or add a comment, sign in
-
We're thrilled to invite you to collaborate with us at the 16th Annual Immunogenicity & Bioassay Summit! 📅 Oct 15-18, 2024 📍 Washington, D.C. 🏢 Meet our experts at Booth #14 Don't miss this opportunity to engage with groundbreaking approaches in immunogenicity assessment, bioassay optimization, and regulatory science. We're proud to present the following key scientific contribution from Dr. Lauren Stevenson: Interactive Discussion: 📆 Oct 16, 2:20 - 3:10 PM "When one size does not fit all: Reevaluating immunogenicity risk assessments and the 3-tiered testing paradigm." Key Topics: * Revising our thinking on risk assessments - incidence without impact and the myth of the medium risk molecule * Lessons learned from over 20 years of data generation - perspectives on benefits and challenges with the current testing paradigm * Mining all the data from the screening tier - how S/N analysis can help fill in the blanks and turn confusion into clarity * Immunogenicity is a biomarker - Understanding the context of use ensures we don't try to put square pegs in round holes and fail to measure what matters * Rethinking the Nab testing tier—if Nab is important to understand, why wait? Differentiating what may be scientifically interesting from what affects patient safety and efficacy. Our team is eager to share insights, answer your questions, and explore potential collaborations. Your next breakthrough could start with a conversation at the summit! #ImmunogenicitySummit2024 #Immunogenicity #Bioanalytical #Bioanalysis #DrugDevelopment #BeAScientist #CRO #LaboratoryServices #Immunologixlabs
To view or add a comment, sign in
-
Join Concept Life Sciences for a webinar hosted by Dr. Thomas Pesnot and featuring Dr. Rob Riley as keynote speaker on the ADMET Toolkit for clinical pharmacokinetics. We hope to see you there! Save your spot, here: https://bit.ly/4dg42Nk Speakers will cover: - What is ADMET and why is it critical to drug discovery? - Why is (predicted) human PK and exposure so key to success? - What are the key ADMET challenges? - How to design a fit-for-purpose screening cascade? - How to anticipate/identify ADMET challenges and develop adapted solutions?
To view or add a comment, sign in
-
By integrating a clinical-grade Knowledgebase with the Clinical Genomics Workspace (CGW), you can quickly make informed decisions regarding patient treatment. The Velsera Knowledgebase offers current information on clinical trials, medical literature, drug labels, and additional relevant data. Utilizing this information, CGW facilitates the automatic assessment of variant significance, enabling the creation of reports that present the most relevant therapeutic options to the treating clinician. This integration not only saves your team time but also ensures the delivery of high-quality clinical results, ultimately leading to the best possible treatment for your patients. Learn more: https://lnkd.in/guXky8s7 #PrecisionMedicine #NGS #Genomics #EraOfVelsera
To view or add a comment, sign in
-
If you’re attending ISCTM in Washington, DC, this week, don’t miss Dr. Joseph Geraci and Dr. Larry Alphs from NetraMark, where they’ll be presenting a poster THURSDAY EVENING on evaluating drug efficacy in clinical trials by leveraging AI-generated insights from placebo response modeling using NetraAI. The NetraAI platform allows scientists to examine small, multimodal datasets in CNS trials to uncover connections related to efficacy, toxicity and placebo response. This accelerates traditional drug development through improved understanding of the underlying disease and mechanism of action, improving clinical trial designs and reducing expensive failures. #NetraAI #ClinicalResearch #CNS #ISCTM
To view or add a comment, sign in
6,743 followers